login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

“We will see steady progress in percutaneous mitral valve therapy over the next couple of years”


Thursday, 15 Mar 2012 11:18
Ted Feldman
Ted Feldman

Catheter-based mitral valve repair with MitraClip is the best-studied type of percutaneous mitral valve therapy, said Ted Feldman, Evanston Hospital, NorthShore University Health System, Evanston, USA, at the International Symposium on Endovascular Therapy (ISET) in Miami.


The EVEREST II (Endovascular valve edge-to-edge repair study) study assessed the safety and effectiveness of the MitraClip device (Abbott Vascular) in patients with significant mitral regurgitation at high risk of surgical mortality rate. The study, published by Feldman et al (N Engl J Med 2011;364:1395–1406), concluded that although percutaneous repair with the MitraClip device “was less effective at reducing mitral regurgitation than conventional surgery, the procedure was associated with superior safety and similar improvements in clinical outcomes.”


A substudy was done on high risk patients. An analysis of the acute and 12-month results of 78 patients showed that the survival rate at one year was 76% in the high risk study and 55% in the concurrent comparator group (p=0.047) of screened concurrently but not enrolled patients.


Feldman showed delegates research behind various other mitral valve devices, including the Carillon Mitral Contour System (Cardiac Dimensions). The TITAN trial showed 40% reduction in mitral regurgitation, improvements in reverse remodeling and functional improvement in patients implanted with the device. “Outcomes in terms of reduced mitral regurgitation and improved chamber function are notable,” he said.


The future of the field may be direct annuloplasty using different delivery devices, including the transventricular approach, which is used in the Mitralign Percutaneous Annuloplasty System or the Guided Delivery System, Feldman said. In this transcatheter procedure, surgical implants are placed directly into the mitral annulus and tensioned through a catheter to reduce the annular circumference, thus mimicking the surgical techniques.


One of the most interesting devices is the Myocor Surgical Coapsys System, he said. This is a novel approach that uses a cathether passed through the left ventricle to reshape the left ventricle and reduce the mitral regurgitation. In the RESTOR-MV (Randomized evaluation of a surgical treatment for off-pump repair of the mitral valve) trial, the system was shown to reduce mortality. The investigators concluded that “patients with functional mitral regurgitation requiring revascularisation treated with ventricular reshaping rather than standard surgery had improved survival and a significant decrease in major adverse outcomes. This trial validates the concept of the ventricular reshaping strategy in this subset of patients with heart failure.”


Another innovation in the field is transcatheter mitral valve replacement, Feldman noted. This approach will use a catheter to deliver a new mitral valve. The major challenge for valve replacement is anchoring of the new valve in the native annulus.


“There is a lot happening in the field, and we will see steady progress over the next couple of years,” Feldman concluded.




Add New Comment

Related Items


Most popular


Mind the gender gap: Addressing inequalities in interventional cardiology
Monday, 14 Dec 2015
With only 4.5% of US interventional cardiologists being female, Cardiovascular News reviews the steps being taken to ensure that being female is not a barrier to being an interventional cardiologist. Mind the gender gap: Addressing inequalities in interventional cardiology

Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension
Wednesday, 06 Jan 2016
The MobiusHD minimally invasive system from Vascular Dynamics has been granted CE mark approval for the treatment of resistant hypertension. Vascular Dynamics’ MobiusHD system receives CE mark for the treatment of resistant hypertension

Orsiro may provide benefit over Xience for STEMI patients
Thursday, 07 Jan 2016
A pre-specified substudy of BIOSCIENCE, published in EuroIntervention, has found that Orsiro is associated with a significantly lower rate of target lesion failure than is Xience in STEMI patients at ... Orsiro may provide benefit over Xience for STEMI patients

Features


Building the ideal heart team for transcatheter mitral valve interventions
Monday, 08 Feb 2016
In this commentary, Vinayak Bapat outlines transcatheter mitral valve interventions and reviews which specialists should comprise the optimal heart team for such procedures. Building the ideal heart team for transcatheter mitral valve interventions

Training is the key to wider adoption of the transradial approach for PCI in the USA
Monday, 25 Jan 2016
This commentary explores why the USA, despite the data supporting the transradial approach, has been more reluctant than other countries to adopt the approach. Training is the key to wider adoption of the transradial approach for PCI in the USA

Profiles


Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions